Cited by 405Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNicotinic Acetylcholine Receptors Study

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Cohen, C., Perrault, G., Voltz, C., Steinberg, R., Soubrié, P.·2002·Behavioural Pharmacology

DOI 10.1097/00008877-200209000-00018

Open this paper in CoChat — free account

Abstract

The central CB(1) cannabinoid receptor has recently been implicated in brain reward function. In the present study we evaluated first the effects of the selective CB(1) receptor antagonist, SR141716, on the motivational effects of nicotine in the rat. Administration of SR141716 (0.3 and 1 mg/kg) decreased nicotine self-administration (0.03 mg/kg/injection). SR141716 (0.3-3 mg/kg) neither substituted for nicotine nor antagonized the nicotine cue in a nicotine discrimination procedure, but dose-dependently (0.01-1 mg/kg) antagonized the substitution of nicotine for D-amphetamine, in rats trained to discriminate D-amphetamine. Secondly, using brain microdialysis, SR141716 (1-3 mg/kg) blocked nicotine-induced dopamine release in the shell of the nucleus accumbens (NAc) and the bed nucleus of the stria terminalis. To investigate whether SR141716 would block the dopamine-releasing effects of another drug of abuse, we extended the neurochemical study to the effect of ethanol, consumption of which in rodents is reduced by SR141716. Dopamine release induced by ethanol in the NAc was also reduced by SR141716 (3 mg/kg). These results suggest that activation of the endogenous cannabinoid system may participate in the motivational and dopamine-releasing effects of nicotine and ethanol. Thus, SR141716 may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation.

Integrity signals

Registry

Crossref · 10.1097/00008877-200209000-00018

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi, M. L., Barth, F., Héaulme, M., Shire, D. J., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,762
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking
Ikemoto, S., & Panksepp, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00023-5 · Cited by 1,450
Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ 1 Opioid Receptor Mechanism
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,085
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829

Show all 77 references

Research works printed but not linked: 3

Cohen, 1999b, NIDA Research Monograph US Department of Health Human Services, 180, 197
deFonseca, 1999, Acta Pharmacol Sin, 20, 1109
De Vries, 2001, Nature, 7, 1511

Sorted by citations

Items 201–300 of 405

Nicotine Self-Administration Induces CB1-Dependent LTP in the Bed Nucleus of the Stria Terminalis
Reisiger, A.-R., Kaufling, J., Manzoni, O. J., Cador, M., Georges, F. E., & Caillé, S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3149-13.2014 · Cited by 37
Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders
Beardsley, P. M., Thomas, B. F., & McMahon, L. R. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782786 · Cited by 35
A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population‐Based Cohort (the HUNT Study)
Wangensteen, T., Akselsen, H. E., Holmen, J., Undlien, D. E., & Retterstøl, L. (2010) · Obesity · doi:10.1038/oby.2010.219 · Cited by 33
The Role of Mesoaccumbens Dopamine in Nicotine Dependence
Balfour, D. J. K. (2015) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-13482-6_3 · Cited by 36
Drug Insight: appetite suppressants
Bray, G. A. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0092 · Cited by 33
Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area
Simonnet, A., Cador, M., & Caillé, S. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00476.x · Cited by 34
CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal
Saravia, R., Flores, Á., Plaza‐Zabala, A., Busquets-García, A., Pastor, A., de la Torre, R., Marzo, V. D., Marsicano, G., Ozaita, A., Maldonado, R. J., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.007 · Cited by 32
Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats
Fang, Q., Li, F., Li, Y., Xue, Y.-X., He, Y., Liu, J., Lü, L., & Wang, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.019 · Cited by 33
Pharmacotherapy for Tobacco Dependence
Fant, R. V., Buchhalter, A. R., Buchman, A. C., & Henningfield, J. E. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_17 · Cited by 34
Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats
Forget, B., Barthélémy, S., Saurini, F., Hamon, M., & Thiébot, M.-H. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0525-x · Cited by 32
Dorsal hippocampal cannabinoid CB1 receptors mediate the interactive effects of nicotine and ethanol on passive avoidance learning in mice
Alijanpour, S., Rezayof, A., & Zarrindast, M. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00387.x · Cited by 31
Metabolic consequences of hyperglycemia and insulin resistance
Jellinger, P. S. (2009) · Insulin · doi:10.1016/s1557-0843(09)80003-1 · Cited by 30
Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation
Kibret, B. G., Canseco-Alba, A., Onaivi, E. S., & Engidawork, E. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1137957 · Cited by 30
Neuroinflammation as a possible link between cannabinoids and addiction
Rodrigues, L. C. M., Gobira, P. H., de Oliveira, A. C., Pelição, R., Teixeira, A. L., Moreira, F. A., & Campos, A. C. (2013) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.24 · Cited by 29
Naloxone and rimonabant reduce the reinforcing properties of exercise in rats.
Rasmussen, E. B., & Hillman, C. N. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0024142 · Cited by 31
Pharmacological approaches to smoking cessation
Mitrouska, I., Bouloukaki, I., & Siafakas, N. M. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.10.012 · Cited by 30
Smoking cessation therapy with varenicline
Krishna, G. (2008) · International Journal of COPD · doi:10.2147/copd.s1848 · Cited by 28
The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine
Paterson, N. E. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832c7083 · Cited by 27
Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats
Biała, G., Budzyńska, B., & Staniak, N. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.042 · Cited by 27
Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats
Budzyńska, B., Kruk, M., & Biała, G. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70036-2 · Cited by 27
Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
Soler‐Cedeño, O., & Xi, Z. (2022) · Cells · doi:10.3390/cells11203262 · Cited by 26
Role of endocannabinoids in regulating drug dependence
Parolaro, D. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s976 · Cited by 26
Bioisosteric Replacement of the Pyrazole 5-Aryl Moiety ofN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A Novel Series of Alkynylthiophenes as Potent and Selective Cannabinoid-1 Receptor Antagonists
Tseng, S.-L., Hung, M., Chang, C., Song, J., Tai, C., Chiu, H.-H., Hsieh, W.-P., Lin, Y., Chung, W.-L., Kuo, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800066v · Cited by 26
Influence of Chronic Nicotine Administration on Cerebral Type 1 Cannabinoid Receptor Binding: An In Vivo Micro-PET Study in the Rat Using [18F]MK-9470
Gérard, N., Ceccarini, J., Bormans, G. M., Vanbilloen, B., Casteels, C., Goffin, K. E., Bosier, B., Lambert, D. M., & Laere, K. V. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9340-2 · Cited by 25
p-Trifluoromethyl- and p-pentafluorothio-substituted curcuminoids of the 2,6-di[(E)-benzylidene)]cycloalkanone type: Syntheses and activities against Leishmania major and Toxoplasma gondii parasites
Nasr, I. S. A., Hanachi, R., Said, R. B., Rahali, S., Tangour, B., Abdelwahab, S. İ., Farasani, A. M., Taha, M. M. E., Bidwai, A. K., Koko, W. S., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105099 · Cited by 24
Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice
Trigo, J. M., & Foll, B. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4117-5 · Cited by 25
Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol
Biała, G., & Budzyńska, B. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70340-6 · Cited by 25
Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance
Everett, T. J., Gomez, D. M., Hamilton, L. R., & Oleson, E. B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110031 · Cited by 24
Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system
Piazza, P. V., Lafontan, M., & Girard, J. R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.002 · Cited by 23
The effect of cannabinoid CB1 receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats
Dyr, W., Ligięza, J., & Kostowski, W. (2008) · Alcohol · doi:10.1016/j.alcohol.2008.04.001 · Cited by 23
Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine‐induced dopamine release in the mouse nucleus accumbens
Pavón, F. J., Serrano, A., Sidhpura, N., Polis, I. Y., Stouffer, D. G., de Fonseca, F. R., Cravatt, B. F., Martin‐Fardon, R., & Parsons, L. H. (2017) · Addiction Biology · doi:10.1111/adb.12531 · Cited by 25
The lack of CB1 receptors prevents neuroadapatations of both NMDA and GABAA receptors after chronic ethanol exposure
Warnault, V., Houchi, H., Barbier, E., Pierrefiche, O., Vilpoux, C., Ledent, C. A., Daoust, M., & Naassïla, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04577.x · Cited by 23
Ethanol does not affect discriminative-stimulus effects of nicotine in rats
Foll, B. L., & Goldberg, S. R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.06.051 · Cited by 23
1-Benzhydryl-3-phenylurea and 1-Benzhydryl-3-phenylthiourea Derivatives: New Templates among the CB1 Cannabinoid Receptor Inverse Agonists
Muccioli, G. G., Wouters, J., Scriba, G. K. E., Poppitz, W., Poupaert, J. H., & Lambert, D. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503906 · Cited by 23
Emerging pharmacotherapies for smoking cessation
Garwood, C. L., & Potts, L. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060427 · Cited by 22
Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry
McCulloch, M., Zhou, X., Xu, Y., Brunell, S. C., & SPEAR, L. P. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.01.020 · Cited by 22
Involvement of the endocannabinoid system in alcohol dependence: The biochemical, behavioral and genetic evidence
Erdozain, A. M., & Callado, L. F. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.02.003 · Cited by 21
Expanding treatment of tobacco dependence
Harris, D. S., & Anthenelli, R. M. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0034-3 · Cited by 21
Effects of a cannabinoid receptor (CB) 1 antagonist AM251 on behavioral sensitization to nicotine in a rat model of novelty-seeking behavior: correlation with hippocampal 5HT
Bhatti, A. S., Aydin, C., Oztan, O., Ma, Z., Hall, P., Tao, R., & Isgor, C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1366-6 · Cited by 21
Cannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach
Foll, B. L., Pushparaj, A. P., Pryslawsky, Y., Forget, B., Vemuri, K. V., Makriyannis, A., & Trigo, J. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.009 · Cited by 20
Lipids and drugs of abuse
Hillard, C. J. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.004 · Cited by 21
The Effects of Glutamate and GABA Receptor Antagonists on Nicotine-induced Neurotransmitter Changes in Cognitive Areas*
Fallon, S. M., Shearman, E., Sershen, H. W., & Lajtha, Á. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9113-z · Cited by 21
CB1 Cannabinoid Receptor Antagonists
Barth, F. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40007-x · Cited by 21
Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: Effects of the cannabinoid receptor 1 antagonist AM251
Aydın, Ç., Oztan, O., & Isgor, C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.016 · Cited by 20
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 20
Human Cannabinoid Pharmacokinetics and Interpretation of Cannabinoid Concentrations in Biological Fluids and Tissues
Huestis, M. A., & Smith, M. L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-947-9_9 · Cited by 19
Tolerance to Ethanol or Nicotine Results in Increased Ethanol Self-Administration and Long-Term Depression in the Dorsolateral Striatum
Abburi, C., Wolfman, S. L., Metz, R. A. E., Kamber, R., McGehee, D. S., & McDaid, J. (2016) · eNeuro · doi:10.1523/eneuro.0112-15.2016 · Cited by 18
WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release
Rodvelt, K. R., Bumgarner, D. M., Putnam, W. C., & Miller, D. K. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.09.020 · Cited by 18
Acute and chronic modulation of striatal endocannabinoid‐mediated plasticity by nicotine
Adermark, L., Morud, J., Lotfi, A., Ericson, M., & Söderpalm, B. (2018) · Addiction Biology · doi:10.1111/adb.12598 · Cited by 17
HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)
Barré, T., Mercié, P., Marcellin, F., Esterle, L., Duvivier, C., Teicher, E., Bureau, M., Chas, J., Salmon, D., Sogni, P., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03277-x · Cited by 17
Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB1 Receptor Antagonists after the Fall
Bosquez-Berger, T., Szanda, G., & Straiker, A. J. (2023) · Drugs and Drug Candidates · doi:10.3390/ddc2030035 · Cited by 17
Impacts of cannabinoid receptor ligands on nicotine- and chronic mild stress-induced cognitive and depression-like effects in mice
Pękała, K., Michalak, A., Kruk-Słomka, M., Budzyńska, B., & Biała, G. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.03.019 · Cited by 16
Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models
Smith, L. C., & George, O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108225 · Cited by 18
The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
López‐Moreno, J. A., González‐Cuevas, G., & Navarro, M. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.010 · Cited by 16
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
Järbe, T. U. C., LeMay, B. J., Vemuri, K. V., Vadivel, S. K., Zvonok, A. M., & Makriyannis, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2226-3 · Cited by 15
A second‐order schedule of food reinforcement in rats to examine the role of CB1 receptors in the reinforcement‐enhancing effects of nicotine
Wing, V. C., & Shoaib, M. C. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00203.x · Cited by 15
Exposure to tobacco smoke during the early postnatal period modifies receptors and enzymes of the endocannabinoid system in the brainstem and striatum in mice
Torres, L. H., Balestrin, N. T., Spelta, L. E. W., Duro, S. D. O., Pistis, M., & Marcourakis, T. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.12.002 · Cited by 15
New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence
Saravia, R., Ten-Blanco, M., Pereda-Pérez, I., & Berrendero, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413316 · Cited by 14
Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation
Butler, K., & Foll, B. L. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1767581 · Cited by 14
Neuropsychopharmacologie du delta-9-tétrahydrocannabinol (THC)
Costentin, J. (2008) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2008.07.003 · Cited by 15
New therapeutic potential for psychoactive natural products
Prevatt‐Smith, K. M., & Prisinzano, T. E. (2009) · Natural Product Reports · doi:10.1039/b912196j · Cited by 14
The psychobiology of nicotine dependence
Balfour, D. J. K. (2008) · European Respiratory Review · doi:10.1183/09059180.00011001 · Cited by 14
Nicotine Addiction: Past and Present
Office on Smoking (2010) · Cited by 14
Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms
Roeder, N. M., Richardson, B., Mihalkovic, A., Penman, S. L., White, O., Hamilton, J., Gupta, A., Blum, K., Gold, M. S., & Thanos, P. K. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010007 · Cited by 13
THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice
Flores, Á., Maldonado, R. J., & Berrendero, F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05416-8 · Cited by 13
Behavioral evidence for the interaction between cannabinoids and Catha edulis F. (Khat) in mice
Kibret, B. G., Onaivi, E. S., & Engidawork, E. (2016) · Brain Research · doi:10.1016/j.brainres.2016.08.006 · Cited by 13
Adult consequences of repeated nicotine and Δ9-tetrahydrocannabinol (THC) vapor inhalation in adolescent rats
Gutierrez, A., Creehan, K. M., Grant, Y., & Taffe, M. A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06545-5 · Cited by 12
Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats
Murray, J. E., Wells, N. R., Lyford, G. D., & Bevins, R. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1572-x · Cited by 12
Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal
Evans, D. E., Sutton, S. K., Jentink, K. G., Lin, H., Park, J. Y., & Drobes, D. J. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.12311 · Cited by 12
Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice
Muldoon, P. P., Akinola, L. S., Schlosburg, J. E., Lichtman, A. H., Sim‐Selley, L. J., Mahadevan, A., Cravatt, B. F., & Damaj, M. I. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108170 · Cited by 12
Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats
Kelsey, J. E., & Calabro, S. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0913-x · Cited by 12
Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli
Laricchiuta, D., Musella, A., Rossi, S., & Centonze, D. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00183 · Cited by 11
Epigenetic mechanisms associated with addiction-related behavioural effects of nicotine and/or cocaine: implication of the endocannabinoid system
Hayase, T. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000326 · Cited by 11
Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment
Bozinoff, N., & Foll, B. L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1507736 · Cited by 11
Adenosine receptor mediates nicotine-induced antinociception in formalin test
Homayounfar, H., Jamali-Raeufy, N., Sahebgharani, M., & Zarrindast, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.08.002 · Cited by 11
Extinction learning of rewards in the rat: is there a role for CB1 receptors?
Hernández, G., & Cheer, J. F. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2275-7 · Cited by 11
Neurobiology of Stress-Induced Nicotine Relapse
Wang, X., Chen, Y., Dong, J., Ge, J., Liu, X., & Liu, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031482 · Cited by 10
Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability
Crunelle, C. L., van de Giessen, E., Schulz, S., Vanderschuren, L. J. M. J., de Bruin, K. M., van den Brink, W., & Booij, J. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00369.x · Cited by 11
The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers
Chukwueke, C. C., Kowalczyk, W. J., Gendy, M. N. S., Taylor, R., Tyndale, R. F., Foll, B. L., & Heishman, S. J. (2020) · Brain and Behavior · doi:10.1002/brb3.1982 · Cited by 10
Contribution of Animal Models and Preclinical Human Studies to Medication Development for Nicotine Dependence
Markou, A., Chiamulera, C., & West, R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00026-6 · Cited by 10
Second‐order schedules of nicotine reinforcement in rats: effect of AM251
Wing, V. C., & Shoaib, M. C. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00204.x · Cited by 10
Nicotine
Koob, G. F., & Moal, M. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012419239-3/50043-6 · Cited by 10
Hypothalamic Regulatory Pathways and Potential Obesity Treatment Targets
Jobst, E. E., Enriori, P. J., Sinnayah, P., & Cowley, M. A. (2006) · Endocrine · doi:10.1385/endo:29:1:33 · Cited by 10
Topiramate does not alter nicotine or cocaine discrimination in rats
Foll, B. L., Justinová, Z., Wertheim, C. E., Barnes, C., & Goldberg, S. R. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f3cf84 · Cited by 10
Recent advances in the treatment of tobacco dependence
Anthenelli, R. M. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.014 · Cited by 10
Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management
Finer, N., & Pagotto, U. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050030201 · Cited by 10
Molecular brain differences and cannabis involvement: A systematic review of positron emission tomography studies
Xu, H., Owens, M. M., Farncombe, T. H., Noseworthy, M. D., & MacKillop, J. M. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.045 · Cited by 9
Structural, QSAR, machine learning and molecular docking studies of 5-thiophen-2-yl pyrazole derivatives as potent and selective cannabinoid-1 receptor antagonists
Hanachi, R., Said, R. B., Allal, H., Rahali, S., Alkhalifah, M. A. M., Alresheedi, F. I., Tangour, B., & Hochlaf, M. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02261j · Cited by 9
Suppressing Effect of the Cannabinoid CB1 Receptor Antagonist, Rimonabant, on Alcohol Self-Administration in Alcohol-Preferring Rats
Maccioni, P., Fantini, N., Carai, M. A. M., Gessa, G. L., & Colombo, G. (2009) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800902020040 · Cited by 9
Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade
Gendy, M. N. S., Ibrahim, C., Sloan, M. E., & Foll, B. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_253 · Cited by 10
Effects of dual use of e-cigarette and cannabis during adolescence on cigarette use in young adulthood
Islam, T. S., Eckel, S. P., Liu, F., Barrington‐Trimis, J. L., Harlow, A. F., Benowitz, N. L., Leventhal, A. M., McConnell, R., & Cho, J. (2023) · Tobacco Control · doi:10.1136/tc-2022-057542 · Cited by 8
The endocannabinoid system:A new approach to control cardiovascular disease
Cannon, C. P. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80064-x · Cited by 8
Interactions between the Nicotinic and Endocannabinoid Receptors at the Plasma Membrane
Vallés, A. S., & Barrantes, F. J. (2022) · Membranes · doi:10.3390/membranes12080812 · Cited by 7
The co-use of nicotine and prescription psychostimulants: A comprehensive review of their behavioral and neuropharmacological interactions
McNealy, K. R., Weyrich, L., & Bevins, R. A. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109906 · Cited by 8
Pharmakologische Rückfallprävention bei Alkohol- und Tabakabhängigkeit
Diehl, A., & Mann, K. F. (2006) · Der Internist · doi:10.1007/s00108-006-1755-z · Cited by 8
Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction
Heidbreder, C. A. (2005) · Current Psychiatry Reviews · doi:10.2174/1573400052953538 · Cited by 8
Pharmacokinetic differences in nicotine and nicotine salts mediate reinforcement-related behavior: an animal model study
Han, P., Jing, X., Han, S., Wang, X., Li, Q., Zhang, Y., Yu, P., Liu, X.-A., Wu, P., Chen, H., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1288102 · Cited by 8
Interactions of Cannabinoids With Biochemical Substrates
Thomas, B. F. (2017) · Substance Abuse Research and Treatment · doi:10.1177/1178221817711418 · Cited by 7
Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes
Grant, P. S., Kahlcke, N., Govindpani, K., Hunter, M. R., Macdonald, C. E., Brimble, M. A., Glass, M., & Furkert, D. P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126644 · Cited by 8

Authors: Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P.
Affiliations: Sanofi (France) (FR)
Corresponding author: Cohen, C.
Venue: Behavioural Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2002-09
Volume: 13
Issue: 5
Pages: 451-463
ISSN: 0955-8810 (ISSN-L)
DOI: 10.1097/00008877-200209000-00018
OpenAlex: W2001109168
Cited by: 396
References: 77
Citations by year: 2026: 5 · 2025: 2 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 7 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 9 · 2013: 19 · 2012: 16
FWCI: 16.34
Type: journal article
Language: en
Open access: closed
Locations: Behavioural Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords: SR141716, nicotine self-administration, dopamine release, nucleus accumbens shell, bed nucleus of the stria terminalis, endocannabinoid system, drug reward, alcohol consumption reduction, smoking cessation
MeSH terms: Rimonabant, Ethanol, Animals, Brain Chemistry, Central Nervous System Depressants, Discrimination Learning, Dopamine, Extracellular Space, Male, Motivation, Nicotine, Nucleus Accumbens, Piperidines, Pyrazoles, Receptors, Drug, Reinforcement, Psychology, Self Administration, Rats, Sprague-Dawley, Rats, Wistar, Microdialysis, Nicotinic Agonists, Nicotinic Antagonists, Receptors, Cannabinoid, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks